Pharma BD Deal Intelligence
The $21.4B acquisition that created Cytiva—the largest deal in bioprocessing history. Danaher gained GE's biopharma business including chromatography resins and single-use technologies essential for virtually every biologic drug manufactured globally. A picks-and-shovels bet.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Danaher Corporation announced a definitive agreement to purchase GE Life Sciences Biopharma division for approximately $21.4 billion in cash, a business…
Cytiva rises as Danaher completes $21 billion deal, the largest ever acquisition in the bioprocess space, adding the biopharma business unit of GE Healthcare.
Danaher Corporation 10-Q filing reporting the completion of its acquisition of the Biopharma business of GE Healthcare Life Sciences.
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Danaher acquired the Biopharma business of GE Healthcare Life Sciences for $21.4 billion (announced Feb 25, 2019; closed March 31, 2020), the largest acquisition in bioprocessing history. The business was rebranded as Cytiva and became a standalone operating company within Danaher's Life Sciences segment, with ~$3.3 billion in revenue and nearly 7,000 employees at close. To satisfy FTC regulatory conditions, Danaher divested certain affinity/ion-exchange resin, chromatography hardware, biomolecular-characterization and tangential-flow-filtration businesses to Sartorius AG; that sale completed April 30, 2020 for approximately $825 million. The picks-and-shovels thesis has since been validated: in September 2022 Danaher announced merging Cytiva with Pall Corporation's life-sciences business to form a single Biotechnology Group (~$8.5 billion combined revenue, ~$7.5 billion of it bioprocessing), completed in 2023. Cytiva revenue roughly doubled from $3.3 billion to ~$6 billion within a few years of close, and Cytiva tooling now supports the large majority of global monoclonal-antibody manufacturing.
Danaher agrees to acquire GE Life Sciences Biopharma business for $21.4B in cash, the largest-ever bioprocess acquisition, targeting biologic drug manufacturing tools and services.
Regulatory reviews in the U.S. and EU extend the expected Q4 2019 close date as authorities examine overlap between Danaher (Pall) and GE biopharma assets.
Danaher completes the $21.4B acquisition three months late. The business is rebranded as Cytiva and becomes a standalone operating company within Danaher Life Sciences segment.
Danaher sells biomolecular characterization, chromatography, and TFF businesses to Sartorius AG for ~$825M to satisfy regulatory conditions for the Cytiva acquisition.
Cytiva generates over $4B in first-year revenue (25% growth), driven by surging demand for bioprocessing tools used in COVID-19 vaccine and therapeutic manufacturing.
Cytiva reaches $6B in annual revenue during peak pandemic-era bioprocessing demand, doubling from $3B pre-acquisition run-rate in under two years.
Danaher merges Cytiva with Pall Corporation to form a new Biotechnology Group, creating a $7.5B bioprocess juggernaut as pandemic-era demand normalizes.
Danaher bought the #1 bioprocess platform at $21.4B and it generated $6B revenue within 18 months, powered by pandemic demand. Even as post-COVID normalization reduced volumes, the Cytiva-Pall merger created a dominant $7.5B bioprocess franchise. Classic Danaher playbook: buy, brand, optimize, scale.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Danaher Corporation / GE Life Sciences Biopharma Business (now Cytiva) (this deal) | 2019 | $21.4B | 76 |
| Danaher Corporation / Pall Corporation | 2015 | $13.6B | 77 |
| Danaher Corporation / Abcam PLC | 2023 | $5.7B | 77 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Becton, Dickinson and Company / C.R. Bard Inc. | 2017 | $24.0B | 77 |
| Johnson & Johnson / Synthes Inc. | 2011 | $19.7B | 77 |
← Browse all deals · How we score deals
More: 2019 deals · Danaher Corporation deals · Multiple (undisclosed) deals